title: Glucocorticosteroid treatment of asthma.
abstract: Inhaled glucocorticoids are currently an important part of asthma management. There is no evidence that the more recently introduced inhaled agents, which have high topical activity and low systemic bioavailability, are unsafe at doses below 2000 micrograms/d. The choice of the delivery device for inhaled glucocorticosteroids is as important as the choice of the particular drug.
authors.affiliation: Department of Medicine, University of British Columbia, Vancouver.
authors.forename: T R
authors.initials: TR
authors.lastname: Bai
mesh_terms: D001249:Asthma / Q000188:drug therapy* / Q000191:economics / Q000378:metabolism; D001682:Biological Availability; D003365:Costs and Cost Analysis; D016503:Drug Delivery Systems / Q000295:instrumentation; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000191:economics / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D010342:Patient Acceptance of Health Care; D013997:Time Factors
chemical_list: D005938:Glucocorticoids